Navigation Links
Steroids after surgery do not help infants with rare liver disease
Date:5/3/2014

Steroids after surgery do not help infants with rare liver disease

Infants with biliary atresia a rare liver disease did not benefit from corticosteroid treatment after bile duct surgery and could face more harm, according to a study funded by the National Institutes of Health. Results were published online May 3 in the Journal of the American Medical Association to coincide with the Pediatric Academic Societies annual meeting.

In biliary atresia, inflammation leads to blockage of the large bile ducts. Bile becomes trapped, causing damage to the liver and leading to scarring, loss of liver tissue and liver failure. Most infants with this serious disease require bile duct surgery and may later need a liver transplant. Worldwide, biliary atresia is the most common reason for liver transplantation in children.

The Steroids in Biliary Atresia Randomized Trial (START) set out to determine whether giving high-dose steroids to infants with biliary atresia after bile duct surgery (hepatoportoenterostomy, also known as the Kasai procedure) is better than surgery alone to maintain bile flow and preserve the children's livers.

Some previous studies suggested that using steroids after surgery reduced inflammation and scarring, promoting bile flow. Those studies became the foundation for widespread use of steroids after bile duct surgery in the United States and elsewhere. But the studies were limited in their ability to assess potential benefits and risks of using steroids in infants.

"We know that the surgery restores the flow of bile, relieves pain and delays the need for liver transplants in many infants, but we did not have data to prove that adding steroids significantly improved bile drainage in infants who had their own livers," said Averell H. Sherker, M.D., project scientist for the Childhood Liver Disease Research and Education Network (ChiLDREN) at the NIH's National Institute of Diabetes and Digestive and Kidney Diseases.

START was conducted at 14 clinical centers. The study enrolled 140 infants with biliary atresia (mean age 10 weeks) between September 2005 and February 2011 and followed them until January 2013. Half were randomly assigned to receive steroids for 13 weeks. The other half received placebo. The drugs or placebo were started within 72 hours of the Kasai procedure, in which a surgeon removes the infant's damaged bile duct and attaches it to a loop of intestine to allow bile to flow from the liver to the small intestine. Without the surgery, infants with biliary atresia are unlikely to live past age 2 without a liver transplant.

Researchers found that steroids did not significantly improve bile flow in infants 6 months after surgery. Fifty-eight percent of infants on steroids achieved improved bile drainage compared to 48.6 percent of those in the placebo group. Results also revealed that survival rates were nearly the same, with 58 percent of infants treated with steroids and about 59 percent of infants receiving placebo still living with their own livers at age 2. While members of both groups had serious adverse events, 37 percent of those on steroids experienced their first complication within 30 days of surgery, compared to 19 percent in the placebo group. These adverse events included surgical complications, infections and bleeding in the digestive tract.

"These findings were unexpected and we hope that doctors who care for these infants thoroughly consider the risks and benefits of corticosteroids in these very vulnerable children," said Jorge A. Bezerra, M.D., lead author and professor of pediatrics of Cincinnati Children's Hospital Medical Center.

Biliary atresia affects about 1 out of every 5,000 to 18,000 infants and progresses to liver failure in more than 70 percent of babies with the disease. It is more common in females, premature babies, and children of Asian or African-American heritage.

"We are grateful to the parents who enrolled their infants in START," said NIDDK Director Griffin P. Rodgers, M.D. "With their help, we learned that by reducing the use of commonly prescribed steroids we might give infants with this devastating disease a better chance for a healthier life, and researchers can continue to investigate treatment alternatives."


'/>"/>

Contact: Leslie Curtis
NIDDKMedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Related medicine news :

1. Giving steroids during bypass surgery shows no benefit, some harm
2. Inhaled corticosteroids raise pneumonia risk
3. Allegheny Health Network Allergist Opposes OTC Sales of Corticosteroids in FDA Testimony, Citing Safety Concerns
4. Vitamin and Supplement Attorneys at Gilman Law, LLP Are Investigating FDA Claims of Anabolic Steroids As Ingredients in Healthy Life Chemistry by Purity First B-50
5. Generic Supplements Offers High Quality Pharmaceutical Grade Anabolic Steroids
6. Canakinumab allows discontinuation of corticosteroids in patients with SJIA
7. Fact or Fiction: Do Legal Steroids Work as Well as the Real Stuff?
8. COPD Patients May Do Fine With Shorter Course of Steroids
9. Anabolic steroids may affect future mental health
10. Certain Steroids May Raise Risk of Dangerous Blood Clots
11. Study: 15% of Children Ages 10 - 14 Consider Using Steroids; polyDNA Recommends Muxscle for Safe Muscle Building
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... Lewisville, TX (PRWEB) , ... July 24, 2017 ... ... grants under the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State ... State of California Department of Health Care Services, will facilitate the development of ...
(Date:7/24/2017)... ... 2017 , ... Peruvian Ayahuasca retreat, East West Lodge, announced ... and divided between two full-time university students enrolled in U.S. or Canadian accredited ... apply for the scholarship, students are asked to submit an essay between 750 ...
(Date:7/24/2017)... ... , ... Axiad IDS , a leading provider of trusted identities for ... to expand its solution to help government contractors more quickly and cost-effectively comply ... to address the authentication requirements within NIST SP800-171, but no matter how you ...
(Date:7/24/2017)... ... ... people are taking more steps to protect themselves from sunburn, half of all adults and ... the past year. It’s common and people have been dealing with them since the dawn ... conscientious of the risks that accompany sunburns. , The team at AloeVera.com , a ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... August 13-17 in National Harbor, MD. This year's theme focuses on the new ... principal benchmarks for quality and integrity in testing and calibration will be changed. ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
(Date:7/5/2017)... England , July 5, 2017 Wolfmet ... perfect answer as physics and manufacturing combine to progress molecular ... thyroid, existing SPECT systems are unable to accurately quantify the ... only limited information regarding the success of this radiotherapy treatment ... ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology: